Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Theratechnologies Establishes New At-The-Market Facility

<< Previous

Bullboard Posts

Next >>

Comment by archeo753on Jul 24, 2021 11:59am

101 Views

Post# 33600846

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Theratechnologies Establishes New At-The-Market Facility

My first thought was that Cantor might have some clients that want shares at today's price and don't want to drive up the share price by aquiring in the open market. TH could release these ATM shares until they get their fill therefore dilluting legacy shareholders at what we all see as a discount to what the TH should be selling for. Glad to see others here have more positive views of the ATM stategy.

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property